The EGFR mutation is the most common driver mutation in over 60% of non–small cell lung cancer (NSCLC) cases, which is a main pathological type of lung cancer.34 The partial deletion of the 19th exon, also known as EGFR (Del19), occurs most frequently and is widely studied as a transgenic model for lung cancer research and therapy.35,36 In this study, we used a mouse model, TetO-EGFR(Del19);CC10-rtTA, by crossing transgenic mice TetO-EGFR (Del19) with CC10-rtTA. This evidence concerns the gene EGFR and lung cancer.